Discovery of a Copper-Based Mcl‑1 Inhibitor as an Effective Antitumor Agent
journal contributionposted on 28.08.2020, 16:11 authored by Xing Lu, Yan-Cheng Liu, Chris Orvig, Hong Liang, Zhen-Feng Chen
Myeloid cell leukemia 1 (Mcl-1), which belongs to the Bcl-2 family of prosurvival proteins, is a key regulator of cancer cell survival. To date, few drug-like Mcl-1 inhibitors have been reported. Herein, we report the preparation of 10 copper complexes with 9-substituted β-carboline ligands that act as metal-based Mcl-1 inhibitors. Complex 14 was identified as a potent and selective Mcl-1 inhibitor with strong in vitro antitumor activity. Mechanistic studies demonstrated that complex 14 disrupted Mcl-1-Bax/Bak heterodimerization and induced Bax/Bak-dependent apoptosis. In addition, complex 14 significantly (P < 0.001) inhibited tumor growth in vivo, induced tumor necrosis, and extended survival time in an NCI-H460 xenograft model. Furthermore, complex 14 showed no apparent toxicity in mice. Together, these findings indicate that complex 14 is a copper-based Mcl-1 inhibitor with high efficacy and low toxicity that could be developed for the treatment of Mcl-1-related cancers.
Read the peer-reviewed publication
NCI-H 460 xenograft modelcancer cell survivalMcl -1-Bax heterodimerizationprosurvival proteinstumor necrosisMcl -1-related cancersBcl -2 familyantitumor activityMechanistic studiesβ- carboline ligandsComplex 14Effective Antitumor Agent Myeloid c...10 copper complexesmetal-based Mclsurvival timetumor growthinhibitordrug-like Mcl